Austar Lifesciences Limited
AULSF
$0.02
-$0.05-71.43%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.21% | -1.88% | -5.27% | -11.19% | -16.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.21% | -1.88% | -5.27% | -11.19% | -16.40% |
| Cost of Revenue | 3.40% | -1.99% | -6.58% | -12.35% | -17.43% |
| Gross Profit | -2.52% | -1.43% | 0.27% | -6.28% | -12.06% |
| SG&A Expenses | -6.88% | -9.60% | -11.53% | -21.53% | -29.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 33.89% | 1.34% | -53.50% | -85.04% | -128.57% |
| Total Operating Expenses | 1.69% | -3.65% | -8.12% | -14.59% | -20.18% |
| Operating Income | 24.15% | 206.11% | 489.15% | 239.02% | 183.69% |
| Income Before Tax | 126.90% | 3,556.75% | 324.95% | 218.89% | 161.37% |
| Income Tax Expenses | 101.16% | 121.83% | 169.22% | 331.29% | 1,539.29% |
| Earnings from Continuing Operations | 141.32% | 864.49% | 248.29% | 181.29% | 138.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -63.68% | -42.67% | -24.48% | -8.33% | 13.23% |
| Net Income | 109.39% | 233.87% | 152.06% | 128.12% | 114.03% |
| EBIT | 24.15% | 206.11% | 489.15% | 239.02% | 183.69% |
| EBITDA | 12.42% | 66.64% | 259.36% | 10,757.01% | 426.64% |
| EPS Basic | 109.09% | 236.23% | 152.75% | 128.46% | 114.15% |
| Normalized Basic EPS | 135.29% | 7,100.00% | 300.00% | 206.52% | 156.67% |
| EPS Diluted | 114.29% | 230.99% | 152.17% | 127.94% | 113.50% |
| Normalized Diluted EPS | 135.29% | 7,100.00% | 300.00% | 206.52% | 156.67% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |